RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Procept Biorobotics Stock

Procept Biorobotics Liabilities 2024

Procept Biorobotics Liabilities

123.96 M USD

Ticker

PRCT

ISIN

US74276L1052

In 2024, Procept Biorobotics's total liabilities amounted to 123.96 M USD, a 10.39% difference from the 112.3 M USD total liabilities in the previous year.

Procept Biorobotics Aktienanalyse

What does Procept Biorobotics do?

PROCEPT BioRobotics Corp (PROCEPT) is a California-based medical technology company specializing in the development of robotic technologies for urological surgery. History: PROCEPT was founded in 2013 by Dr. Chin and his group at Johns Hopkins University School of Medicine. They developed a novel technology that had the potential to revolutionize the treatment of prostate cancer. PROCEPT used a robust Intuitive Surgical platform and developed a novel tissue classification technology that allows surgeons to operate with accuracy and safety. The first system, called AquaBeam®, was approved by the US Food and Drug Administration (FDA) in 2018 and has since been in use in Europe and the US. Business: PROCEPT aims to improve urological surgery through the use of robotic technologies, thereby increasing patient safety and care. The company focuses on the development and commercialization of robotic systems for the treatment of prostate cancer and other urological diseases. Products: PROCEPT has developed Aquablation®, a robotic system for the treatment of prostate cancer. It is a minimally invasive technology that uses high-precision waterjet cutting (accuracy reduced to millimeters) to remove cancerous tissue quickly, effectively, and accurately. The technology can also be used in surgical procedures on the bladder, urethra, and other urological organs. Divisions: PROCEPT has a broad portfolio of services and products in the field of urological surgery. The AquaBeam® technology is the first system developed to treat malignant prostate tumors using robotic technologies. The technology is used in hospitals, clinics, and medical facilities worldwide. In addition, PROCEPT offers training and support for surgeons and medical personnel. Conclusion: PROCEPT BioRobotics Corp is an emerging medical technology company specializing in robotics-based urological surgery. The AquaBeam® technology is an innovative, robotic technology for the treatment of prostate cancer. The company is on its way to revolutionizing urological surgery and making a significant contribution to improving healthcare. Procept Biorobotics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Procept Biorobotics's Liabilities

Procept Biorobotics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Procept Biorobotics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Procept Biorobotics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Procept Biorobotics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Procept Biorobotics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Procept Biorobotics stock

What is the level of liabilities of Procept Biorobotics this year?

Procept Biorobotics has a debt balance of 123.96 M USD this year.

What were the liabilities of Procept Biorobotics compared to the previous year?

The liabilities of Procept Biorobotics have increased by 10.39% increased compared to the previous year.

What are the consequences of high debt for investors of Procept Biorobotics?

High liabilities can pose a risk for investors of Procept Biorobotics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Procept Biorobotics?

Low liabilities mean that Procept Biorobotics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Procept Biorobotics affect the company?

An increase in liabilities of Procept Biorobotics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Procept Biorobotics affect the company?

A decrease in the liabilities of Procept Biorobotics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Procept Biorobotics?

Some factors that can influence the liabilities of Procept Biorobotics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Procept Biorobotics so important for investors?

The liabilities of Procept Biorobotics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Procept Biorobotics take to modify the liabilities?

To change its liabilities, Procept Biorobotics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Procept Biorobotics pay?

Over the past 12 months, Procept Biorobotics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Procept Biorobotics is expected to pay a dividend of 0 USD.

What is the dividend yield of Procept Biorobotics?

The current dividend yield of Procept Biorobotics is .

When does Procept Biorobotics pay dividends?

Procept Biorobotics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Procept Biorobotics?

Procept Biorobotics paid dividends every year for the past 0 years.

What is the dividend of Procept Biorobotics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Procept Biorobotics located?

Procept Biorobotics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Procept Biorobotics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Procept Biorobotics from 12/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/17/2024.

When did Procept Biorobotics pay the last dividend?

The last dividend was paid out on 12/17/2024.

What was the dividend of Procept Biorobotics in the year 2023?

In the year 2023, Procept Biorobotics distributed 0 USD as dividends.

In which currency does Procept Biorobotics pay out the dividend?

The dividends of Procept Biorobotics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Procept Biorobotics

Our stock analysis for Procept Biorobotics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Procept Biorobotics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.